Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A new prevalence study of multiple sclerosis in Orkney, Shetland and Aberdeen city.
A touch of MS: Therapeutic mislabeling.
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis.
Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease.
Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation.
New TYSABRI® data show earlier treatment and longer-term use result in significant reductions in MS disease activity
Immune surveillance in multiple sclerosis patients treated with natalizumab.
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice.
Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System.
Response to disease modifying therapies in African Americans with multiple sclerosis.
The genetics of multiple sclerosis.
HyperCKemia Related to the Initial and Recurrent Attacks of Neuromyelitis Optica.
Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
Accuracy of StepWatch™ and ActiGraph Accelerometers for Measuring Steps Taken among Persons with Multiple Sclerosis.
Merck KGaA Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod (ONO-4641)
Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets.
A new cognitive rehabilitation programme for patients with multiple sclerosis: the 'MS-line! Project'
Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
Targeting the shift from m1 to m2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil.
Clinical assessment of noninvasive intracranial pressure absolute value measurement method.
Evaluating the potential benefit of interferon treatment in multiple sclerosis.
Endogeneous Remyelination: Findings in Human Studies.
Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
Please mind the gap: axonal transport deficits in multiple sclerosis neurodegeneration.

Pages